Specific Inhibitors of Reactive Oxygen Species (ROS) Production

Tech ID:

Texas Health San Antonio researchers have created recombinant mutant versions of NOXA1 and p67phox that inhibit generation of reactive oxygen species (ROS) by NOX enzymes.  These polypeptides may be useful therapeutically as specific inhibitors of ROS overproduction to treat a variety of disease states.



ROS are important for a number of normal biochemical and biological functions in the body, but ROS can lead to disease when overproduced.  The NADPH oxidase (NOX) enzymes catalyze the initial step in the generation of ROS:  the single-electron reduction of molecular oxygen.  The isoforms of NOX are expressed in various tissues, use different cofactors and perform different functions.  NOX2 is expressed in neutrophils and macrophages and is responsible for the respiratory burst, which defends the body against microbial pathogens.  NOX1 is expressed in colon epithelial cells and is believed to function in an anti-microbial capacity as well as in the regulation of cell growth.  The mutated form of NOXA1 blocks NOX1 activation, while its homologue mutated p67phox selectively inhibits NOX2 function.


Commercial Applications:

The pathology of conditions such as aging, atherosclerosis, diabetes, chronic inflammation of the GI tract, aging of the skin, Alzheimer's disease, other neurological disorders and rheumatoid arthritis are linked to the overproduction of ROS.  Some cancer biology studies suggest a potential role for NOX isoforms, especially NOX1, in cell transformation and growth.  Each one of these conditions represents a potentially large therapeutic market.


Benefits and Advantages:

·         Novel specific inhibitors of NOX1 and NOX2 enzymes

·         Recombinant NOXA1 and p67phox mutants inhibit generation of damaging ROS

·         Blocking the formation of tissue-damaging ROS is more effective than use of anti-oxidants or ROS scavenging agents to reduce the effects of ROS overproduction

·         Potentially useful therapeutic compounds for treatment of diseases involving overproduction of ROS, including inflammatory, infectious, vascular, degenerative and neoplastic diseases


IP Status:  U.S. Patent 7,582,606.  Available for exclusive licensing


Patent Information:
For information contact:
Daniel Rafferty
Business Development Manager
Office of Technology Commercialization
Anthony Valente
Robert Clark